On October 22, 2019, Winterlight Labs Inc. closed a $5.6 million round of Series A financing led by Hikma Ventures, the venture capital arm of Hikma Pharmaceuticals. Participation also included First Star Ventures, Pacific Health Ventures, Grey Sky Venture Partners and other investors. Winterlight will use the proceeds of this financing to extend its technology to additional indications, such as schizophrenia and multiple sclerosis, as well as additional languages.
Winterlight Labs was founded in 2015 in Toronto and specializes in computational linguistics, cognitive neuroscience, and machine learning.
Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures invests in global start-ups where Hikma’s expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company.
Osler, Hoskin & Harcourt LLP advised Winterlight with a team consisting of Chad Bayne, Michael Grantmyre and Sahil Chopra (Emerging and High Growth Companies).